Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), a biopharmaceutical company developing first-in-class drug candidates targeting the innate immune system, today announces an operating revenue of 12.9 million Euros for the year 2008. Turnover for the year amounted to 7.5 million Euros, including 1.6 million Euros in the fourth quarter ended December 31, 2008.
